Company Overview
| Stock Name | SKB Bio |
|---|---|
| Stock Code | 06990 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家創新的生物醫藥公司,致力于創新藥物的研發、制造及商業化,以解決中國乃至全球的醫療需求。 |
| Listing Date | 2023-07-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國四川省成都市溫江區成都海峽兩岸科技產業開發園新華大道666號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://kelun-biotech.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 60.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 38.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 136,028,820 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 6,060 |
| 2 lots | 200 | HK$ 12,120 |
| 3 lots | 300 | HK$ 18,180 |
| 4 lots | 400 | HK$ 24,240 |
| 5 lots | 500 | HK$ 30,300 |
| 6 lots | 600 | HK$ 36,360 |
| 7 lots | 700 | HK$ 42,420 |
| 8 lots | 800 | HK$ 48,480 |
| 9 lots | 900 | HK$ 54,540 |
| 10 lots | 1,000 | HK$ 60,600 |
| 15 lots | 1,500 | HK$ 90,900 |
| 20 lots | 2,000 | HK$ 121,200 |
| 25 lots | 2,500 | HK$ 151,500 |
| 30 lots | 3,000 | HK$ 181,800 |
| 35 lots | 3,500 | HK$ 212,100 |
| 40 lots | 4,000 | HK$ 242,400 |
| 45 lots | 4,500 | HK$ 272,700 |
| 50 lots | 5,000 | HK$ 303,000 |
| 60 lots | 6,000 | HK$ 363,600 |
| 70 lots | 7,000 | HK$ 424,200 |
| 80 lots | 8,000 | HK$ 484,800 |
| 100 lots | 10,000 | HK$ 606,000 |
| 150 lots | 15,000 | HK$ 909,000 |
| 200 lots | 20,000 | HK$ 1,212,000 |
| 250 lots | 25,000 | HK$ 1,515,000 |
| 300 lots | 30,000 | HK$ 1,818,000 |
| 350 lots | 35,000 | HK$ 2,121,000 |
| 400 lots | 40,000 | HK$ 2,424,000 |
| 450 lots | 45,000 | HK$ 2,727,000 |
| 500 lots | 50,000 | HK$ 3,030,000 |
| 600 lots | 60,000 | HK$ 3,636,000 |
| 700 lots | 70,000 | HK$ 4,242,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 100,000 | HK$ 6,060,000 |
| 2,000 lots | 200,000 | HK$ 12,120,000 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | --- |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 62.5 |
|---|---|
| First Day Open | HK$ 60.6 |
| First Day Change | 3.14% |
| First Day Volume | 2002300.0 |
| First Day Turnover | 124404000.0 |
| Use of Proceeds | 1、約45.0%或566.5百萬港元將用于研發并商業化核心產品SKB264及A166;
2、約30.0%或377.7百萬港元將用于其他主要產品的研發及商業化;
3、約12.0%或151.1百萬港元將用于為持續開發技術平臺、推進其他現有管線資產以及探索并開發新候選藥物提供資金;
4、約8.0%或100.7百萬港元將用于擴充產能及質量控制系統,以支持后期資產的預期商業化;
5、約5.0%或62.9百萬港元將用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (5)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Laurion Capital Master Fund, Ltd. | 56,939,760 HKD | — | 4.20% | — | 6 months | 2024-01-11 |
| 2 | RTW Funds | 117,224,640 HKD | — | 8.60% | — | 6 months | 2024-01-11 |
| 3 | TruMed | 56,939,760 HKD | — | 4.20% | — | 6 months | 2024-01-11 |
| 4 | 汇添富基金管理股份有限公司 | 65,490,420 HKD | — | 4.80% | — | 6 months | 2024-01-11 |
| 5 | 科伦国际发展有限公司 | 229,231,620 HKD | — | 16.90% | — | 6 months | 2024-01-11 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 劉革新 | — |
| Company Secretary | 周澤劍;鐘明輝 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 四川科倫藥業股份有限公司(55.13%);雇員激勵平臺(13.90%);默沙東(6.23%);Wealthy Linkage(3.37%);先進制造產業投資基金(3.31%) |
|---|




